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Abstract
Background: The use of hormone therapy (HT) by menopausal women has declined since the Women’s Health Initiative
randomized trial (WHI) in 2002 demonstrated important harms associated with long-term use. However, how this
information has influenced women’s knowledge and attitudes is uncertain. We aimed to evaluate the attitudes and
perceptions towards HT use, as well as specific concerns and information sources on HT since the WHI trial.
Method/Results: We did a systematic review to assess the attitudes and knowledge towards HT in women, and estimate the
magnitude of the issue by pooling across the studies. Using meta-synthesis methods, we reviewed qualitative studies and
surveys and performed content analysis on the study reports. We pooled quantitative studies using a random-effects meta-
analysis. We analyzed 11 qualitative studies (n=566) and 27 quantitative studies (n=39251). Positive views on HT included
climacteric symptom control, prevention of osteoporosis and a perceived improvement in quality of life. Negative factors
reported included concerns about potential harmful effects, particularly cancer risks. Sources of information included health
providers, media, and social contact. By applying a meta-synthesis approach we demonstrate that these findings are broadly
applicable across large groups of patients.
Conclusions: Although there are clear hazards associated with long-term HT use, many women view HT favorably for
climacteric symptom relief. Media, as a source of information, is often valued as equivalent to health providers.
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Introduction
Hormone therapy has been one of the most broadly prescribed
medications in recent memory. Although initially recommended
for climacteric symptom control, there was a widespread
understanding in the medical community that HT offered many
favorable additional effects including cardiovascular and neuro-
logical protection [1,2,3]. because menopause naturally occurs
when the ovaries begin decreasing production of estrogen and
progesterone, and induced menopause occurs when the ovaries
are surgically removed by bilateral oophorectomy or damaged by
radiation or drugs, it usually takes 10 years for women to
experience symptomatic changes. This is typically in a woman’s
late forties or early fifties, a time when lifestyle and other
progressive diseases may become apparent. During this stage,
many women experience physical and/or emotional symptoms
[4,5]. For some, symptoms related to menopause importantly
impact their daily personal, professional, and social lives, resulting
in a desire to reduce any adverse symptoms [6,7].
With widespread support of HT for broad health benefits, single
small trials or observational studies did not provide sufficient
evidence to change the larger medical opinion. A large
observational study, the Heart and Estrogen/progestin Replace-
ment Study (HERS) [8] concluded that during 4.1 years of
follow-up, treatment with oral conjugated equine estrogen plus
medroxyprogesterone acetate did not reduce the overall rate of
coronary heart disease (CHD) events in postmenopausal women
with established coronary disease; on the contrary, it increased the
rate of thromboembolic events and gallbladder disease. In 2002,
the Women’s Health Initiative (WHI) randomized trial involving
over 26,000 women [9] was stopped early due to increased risks of
invasive breast cancer, pulmonary embolism, CHD and stroke
when compared with placebo, confirming the findings of the
HERS study [10]. A meta-analyses of observational studies
published in 2002 indicated that HT was associated with long-
term important harms, and a benefit only at osteoporosis
prevention and climacteric relief [11]. The follow-up WHI study
demonstrated HT was responsible for breast cancer and excess
deaths directly attributed to breast cancer [12].
Despite evidence from these large studies, as many as 50% of
physicians remain skeptical toward the evidence from WHI and
HERS, citing concerns with study designs and patient populations
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education has led to concern that benefits of HT are being
unnecessarily promoted and harms are being reduced [14] . For
this reason, it may be challenging for health care providers and
menopausal women to make informed decisions on HT use.
Although the use of HT has decreased [15,16], there is uncertainty
among obstetrician-gynecologists that it may be a viable treatment
option for climacteric symptoms relief such as hot flashes, vaginal
atrophy, osteoporosis and loss of Libido [17]. While studies have
examined the knowledge and perceptions of physician and
healthcare providers about the evidence for HT [13,17,18], no
systematic review about the overall attitude or perception of
menopausal women towards HT exist. In order to summarize
women’s attitudes and knowledge regarding HT use, we applied
a meta-synthesis of published studies [19,20,21], a strategy that
permits reviewers to identify common perceptions and beliefs
and to determine the magnitude of these beliefs with some
confidence.
Figure 1. Flow diagram of included studies.
doi:10.1371/journal.pone.0024661.g001
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Study approach
Our study approach is based on a two-step analysis of the
studies. Firstly, we will identify the themes that are identified in
qualitative studies. Secondly, we will determine the magnitude of
these themes in broader populations by conducting a meta-
analysis of surveys that report the themes. We have published on
these methods extensively in the past [19,20,21,22,23,24].
Eligibility criteria
For stage 1, we included two types of studies, qualitative studies
and quantitative studies that used open-ended questions, allowing
an unlimited number of participant responses. For stage 2, we
Table 1. Study characteristics of qualitative study.
reference country population Main focus of Paper Setting Main findings Design
Walter
2002
54
UK n=40, (50–55 ys,)
75% well- educated
100% peri-menopause,
32.5% never used HT.
Explore women’s under-
standing of the risks
associated with
the menopause and HT.
general
practices
Patients used their knowledge,
risk perception and their individual
belief system, experience, age and
emotions to modify the salience
of HT risk. Most of them favored
communication with health providers.
Sharing experience with the others
would be important to facilitate in
decision making
Focus group/
semi-structured
interviews
French
2006
48
USA n=127,(50–70 ys)
100% well-educated,
100% peri-menopause,
14.2% never used HT
explore the impact of
hormone therapy
recommendations on
patients’ attitude and
decision making
general practice
office
HT should take into account women’s
preferences about symptom relief and
the trade-offs among relevant risks.
Emotional support during transitions
in HT is encouraged
open ended
Ballard
2002
46
UK n=32, (51–57 ys)
34.4% well-educated,
100% peri-menopause,
37.5% never used HT
explore women’s perceived
risk of menopause-related
disease and the decision
making of HT for disease
prevention
community
setting
Osteoporosis and heart disease
are associated with decision to
take HT, which are largely based
on individual assessment of risk,
but the value of HT is limited.
semi-structured
interviews
Cifcili
2009
47
Turkey n=16, (42–53 ys)
63% well-educated,
100% peri-menopause,
no data for HT use
explore women’s
knowledge of
menopause
and HT
gynecological
clinic
Menopause is a natural transition
process; seeking medical help is
a way to cope with it. non-
pharmacological options were
favored because of HT side effects.
semi-structured
interviews
Shelton
2002
53
USA n=75, (30–71 ys)
100% well-educated,
25.6% peri-menopause,
37% never used HT
explore the attitude and
belief about and pattern
of HT use
community
and clinic
Use of HT as either therapeutic
or prevention is controversial. The
target-oriented counseling, taking
into account the individual attitudes
toward HT, is expected
focus group
Loutfy
2006
33
Egypt n=70, (50–59 ys)
21.1% well-educated,
100% peri-menopause,
no one used HT
determine symptoms,
perceptions and practices
after natural menopause
community Most participants had never heard
about HT. Its cost and side-effects
were a concern. Main information
sources included the media.
focus group
Hepworth
2002
49
Australia
Adelaide
n=21,(50–69 ys)
( n od a t ao ne d u c a t i o n
and HT use)
100% peri-menopause,
explore the knowledge/
attitude of HT and patients’
willingness to participate in
a long-term HT randomized
control trial
general
practices
HT was beneficial for symptom relief,
‘ ‘ n a t u r a la p p r o a c ht oh e a l t ha n da n t i -
medication were expected, and more
information about HT was expected.
focus group
Hyde
2010
50
Ireland n=23, (42–63 ys)
no data on education,
100% peri-menopause,
64.1% never used HT
explore women’s
experience
of menopause
and HT
Thematic
Networks
HT effectiveness was in
moderating bodily distresses.
semi-structured
interviews
Kolip
2009
51
Germany n=35, (46–75 ys)
no data on education,
100% peri-menopause,
no one used HT
explore the reason why
postmenopausal women
undergo long-term
hormone therapy
na Target-oriented counseling is
needed; the health providers
should consider patients’ individual
attitudes toward menopause and HT.
semi-structured
interviews
Weltom
2004
55
England
Scotland
n=82, (50–69 ys)
no data on education,
100% peri-menopause,
30% never used HT
explore the factors affecting
HT decision making and the
view about risk and benefits,
attitude towards HT study
results
general
practice
Women regarded taking HT as
highly personal; the reason for
continuation was to improve
quality of life regardless of the
risks in the longer term.
focus group
Nekhlyudov
2009
52
USA n=45, (45–60 ys)
no data on education,
100% peri-menopause,
no one used HT
explore women’s beliefs
about hormone therapy
and breast cancer risk
phone
interview
To control menopausal symptoms
was important and possibly
outweighed the concerns
about the potential
risks of breast cancer.
structured
interviews
doi:10.1371/journal.pone.0024661.t001
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survey populations that affirm the issues raised in qualitative
studies.
Eligible studies had to meet the following criteria: reported as an
original research study and conducted in peri-menopausal women;
contained information addressing attitude or knowledge towards
HT; or information sources on HT. Studies that only compared
the demographic characteristics between HT users and non-users;
evaluated clinical outcomes; evaluated the proportion of HT use;
or conducted within a specific population (eg. patients with breast
cancer or cardiovascular diseases) were excluded.
Search strategy
Using a formal search strategy, MFT and YCT searched the
following databases independently and in duplicate (from 07/
2002 to 01/2011): MEDLINE, AMED, Alt Health Watch,
CINAHL, Nursing and Allied Health Collection: Basic, and the
Cochrane Database of Systematic Reviews. Our search strategy
used permutations and combinations of the following terms:
attitudes, perception, knowledge, behavior and belief, menopause, hormone
treatment, HRT, qualitative, grounded theory, interview, questionnaire,
cross-sectional and, survey. In addition, we supplemented this
search by reviewing the bibliographies of key papers. We
worked together to assess relevant studies for inclusion and only
English language studies were included. MFT and YCT
independently reviewed the abstracts and chose the full articles
after discussion.
Data abstraction and validity assessment
MFT and HFS independently extracted data and appraised
the validity. Disagreements were resolved by a third reviewer
(PW). We extracted data on the methods of the studies using a
modified checklist to assess internal validity [21] [25]. Quanti-
tative studies were not scored as no accepted criteria exist for
judging quality. A coding template to categorize key perceptions
towards HT was developed iteratively during an initial review.
This template consisted of the mutually exclusive headings listed
as the positive factors that enable women to use; the negative
factors that enable women to use; women’ individual character-
istics when making the decision and information sources of HT.
We then read all available surveys to determine whether they
asked questions broadly representative of the themes identified in
the qualitative studies. Data were regarded eligible for inclusion
in the meta-analysis if the study reported proportions of
respondents.
Statistical analyses
We used the k statistic to measure chance-adjusted agreement
between reviewers for study eligibility. When information on
proportions of respondents was available from the quantitative
studies, we calculated weighted proportions of studies using the
Freeman-Tukey method [26]. We calculated an overall estimate of
effect by pooling the proportions of each quantitative study by
applying a random-effects model, with 95% Confidence Intervals
(CI) and lower CI truncated at zero. We assessed heterogeneity of
proportions visually as pooling proportions always results in large
estimates of heterogeneity and statistical techniques do not yet exist
to interpret the extent of real between-study heterogeneity for
proportions [27]. We used Stats Direct for all statistical procedures.
Results
Our search identified 220 relevant abstracts. There was good
(k=0.64) agreement between MFT and YCT on choosing the
final 77 applicable full-text studies for potential inclusion. Of
these studies, 40 were excluded for various reasons, leaving 37
studies [5,7,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,
46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62] included in our
analyses (See figure 1).
We included eleven qualitative studies [40,53,54,55,56,57,
58,59,60,61,62] and 27 quantitative studies [7,28,29,30,31,32,
33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,63],
reporting 31 independent studies. One study [40] included both
qualitative and quantitative study. Table 1 shows the character-
istics of the populations in the qualitative studies and Table 2
shows the methodology of these studies. Among these, 4 studies
[40,56,60,62] used focus groups (n=248), five [53,54,57,58,59]
Table 2. Reporting criteria of qualitative studies.
reference
Walter
2002
[61]
French
2006
[55]
Ballard
2002
[53]
Cifcili
2009
[54]
Shelton
2002
[60]
Loutfy
2006
[40]
Hepworth
2002 [56]
Hyde
2010
[57]
Kolip
2009
[58]
Weltom
2004
[62]
Nekhlyudov
2009 [59]
Was the data transcribed verbatim
(ie. Were audiotapes, videotapes, used?
33 333 33 333 3
If interview conducted, were questions
predefined?
33 333 3 333 3
If focus group used, was the facilitator
trained?
33 3 33 3
Was saturation mentioned? 33 3 3 3
Was there a description of how the
research themes were identified?
33 333 3 333 3
Were participants’ answers reviewed
for clarification?
33 3 3 3 3
Were sequences from the original
data presented?
33 33 333 3
Were the findings analyzed by more
than one assessor?
33 333 3 333 3
3 indicates the methodological item was mentioned in the original study.
doi:10.1371/journal.pone.0024661.t002
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group and semi-structured interviews (n=40) and one [55] used
mainly open-ended questioning (n=127). The attitudes identified
towards HT are listed in Table 3.
The characteristics of all quantitative studies are listed in Table 4
and whether they used structured questionnaires or structured
interviews (n=39,251) to determine the attitude and acknowl-
edgement of HT (see Table 5 for the details). Studies were
Table 3. Attitude towards HT in qualitative studies.
reference
Walter
2002
[61]
French
2006
[55]
Ballard
2002
[53]
Cifcili
2009
[54]
Shelton
2002
[60]
Loutfy
2006
[40]
Hepworth
2002 [56]
Hyde
2010
[57]
Kolip
2009
[58]
Weltom
2004
[62]
Nekhlyudov
2009 [59]
Positive factors that enable
women to use
Effective for climacteric symptoms 33 3 3 33 3
benefit outweighs risk 33 3
Osteoporosis prevention
Treatment of menopause related
disease
3
necessary supplement 33
Improve quality of life 33
MD recommendation 33 3 3
Negative factors that enable
women to use
Potential side effects 3 3 33333 3 33
May cause cancer 3 333 3 3 3 3
May cause CHD
Uncertain evidence 33 3 3 3 3
No benefit or bad solution of HT 3
Distrust HT 3
Against person’s natural healing process 33
Experiment with my body 3
No knowledge about HT 3
Reduce life quality
Not suggested by MD
Women’s individual characteristics
when making the decision
Preference for other treatment 33 3 3 33 3
Unnecessary to use 33
Personal experience, knowledge
against HT use
333 33
Dislike medication/HT isn’t natural 3
Concern of the cost 3
Feel isolation when making decision 3 3
Medical history contraindicate HT use 3
Fear/Mistrust of research 33
Information sources
Media 33
Work and social contact 33 3
Health professional 33 3
Women’s expectation
Communication with MD in decision
making
33 3 3
Belief that MD should make decisions 33 3 3 3
Favor evidence-based information 33 3
Balancing individualized situation 333 3 3 33
3 indicates that the items was reported in the original text.
doi:10.1371/journal.pone.0024661.t003
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39,43,44,45,46,49], North America [7,30,31,37,41,42,50,52],
South America [33], Latin America [7], Oceania [47] and the
Middle East [40].
To generalize the findings from qualitative studies, we pooled
data for the factors reported in quantitative studies. From the
pooled data we found that 47% (95%:34–60%) of participants
perceived that HT was effective for climacteric symptoms, 26%
(95% 15–40%) perceived that HT could be used in osteoporosis
prevention and 33%(19%–48%) thought the benefits of HT
outweigh the risks.
Thirty-one percent (95%CI: 18–46%) were aware of potential
adverse events of HT, 37% (95%: 21–54%) aware HT may cause
cancer and 14% (95%: 3–31% thought the risks of HT overweigh
its benefit. Thirty-four percent (95%CI: 21–48%) thought it was
unnecessary to use HT as the menopause-related symptoms were
tolerable; 35% (95%CI: 24–47%) of respondents felt that the
current evidence on HT was uncertain and 49%(95%CI: 22–76%)
mentioned that they had no knowledge about HT.
For information sources, forty-three percent (95%CI: 26–60%)
obtained menopause- and HT related information from media
including TV, internet, magazines, and newspapers, while 47%
(95%CI: 25–70) obtained information from their health care
provider and 40% (95%CI: 17–65%) from their work or social
contacts. No knowledge of HT was evaluated in 7 studies, and 5 of
them was conducted in developing countries,. We found visible
heterogeneity in all pooled analyses, which we explain by our a
priori hypotheses that findings from developed countries differ from
developing countries in terms of knowledge. Figure 2 shows the
pooled proportions of attitudes that were generated from the
outcomes listed in Table 5.
Discussion
In our current review, we summarized women’s attitude and
perceptions towards HT reported in studies published after the
WHI and found somewhat low levels of concern about serious
adverse events. In addition, with the development of information
Table 4. Characteristics of quantitative studies.
reference Num country age
Education(.9y s )
(%) Response rate (%) Never use HT(%)
Lam PM 2003
21 978 Hong Kong 40–60 47 na 96
Kaur S 2004
22 725 India 40–60 13 na 100
Barber CA 2004
23 185 USA 25–84 72 98 100
Obermeyer CM 2004
24 293 USA 45–55 98 62 71
Ekstrom H 2005
25 1681 Sweden 45–60 49 76 59
Filho A 2005
26 755 Brazil .=35 100 56 29
Hovi S 2005
27 778 Finland 45–64 61 66 90
Chaopotong P 2005
28 148 Thailand .40 87 91 76
Thunell L 2005
1998 29 4095 Sweden .=46 43 76 na
Thunell L2005
1992 29 4504 Sweden .=46 77 76 27
Bosworth HB 2005
30 533 USA 45–54 76 22 50
Genazzani AR 2006
31 4201 Europe 45–60 79 na 58
Sveinsdottir H 2006
32 561 Iceland 47–53 69 56 55
Loutfy I 2006
33 450 Egypt 50–59 21 na 100
Twiss JJ 2007
34 166 USA 40–55 99 na 54
Rigby AJ 2007
35 781 USA 40–60 89 72 66
Uncu Y 2007
36 1007 Turkey 39–89 13 na 83
Castelo-Branco C2007
37 270 Spain 40–65 35 na 33
Lindh L 2007
999 38 1180 Sweden 53–54 na 67 48
Lindh L 2007
2003 39 1239 Sweden 53–54 68 72 56
Heinemann K 2008
3 4791 Europe 40–70 19 70 62
Heinemann K 2008
3 1500 USA 40–70 40 70 57
Heinemann K 2008
3 3006 Latin America 40–70 9 na 80
Heinemann K 2008
3 1000 Indonesia 40–70 4 na 98
Deeks A 2008
40 692 Australia 45–55 na 77 na
Malik HS 2008
41 102 Pakistan 40–75 ‘‘No education’’ 60.8 93 100
Donati S 2009
42 720 Italy 45–64 44 74 84
Huston SA 2009
43 689 USA 45–64 99 42 56
Jassim GA 2009
44 260 Bahrain 30–64 86 na 97
Simon JA 2009
45 961 USA .=35 69 na 59
Huang K 2010 [63] 1000 Asia 45–60 100 na 45
doi:10.1371/journal.pone.0024661.t004
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healthcare and have become a commonly used form of
information. Women in developing countries had lower levels of
knowledge about HT than those in more developed settings.
These findings are concerning for several reasons. First, many
obstetrician-gynecologists have report they were unlikely to change
their prescribing practice following the WHI [17]. And secondly,
emerging evidence indicates sources of information on HT
benefits and harms may be skewed according to the funding body
supporting the messaging, potentially downplaying risks associated
with HT [15].
There are both strengths and weaknesses to consider when
interpreting our study. A novelty of our study is that we
synthesized and conducted a meta-analysis based on issues raised
in qualitative studies and then assessed the magnitude of these
beliefs in larger populations by pooling the answers from the
quantitative studies. We have used this approach several times
previously on unrelated topics [19,20,21,22,23,24] and have
published its methodological assumptions [20,22]. Limitations of
our study lie most inherently in the reporting biases presented in
the included qualitative studies. Unlike protocol driven studies,
such as randomized trials, where the outcomes should be
established prior to the conduct of the study, one cannot determine
what issues will be conclusively raised in qualitative studies. Thus,
it is possible that some issues raised by participants are not
reported in the final manuscripts. For that reason, we believe our
approach is specific but not necessarily sensitive, our approach to
pooling utilized proportions, an infrequently used metric to apply
meta-analysis to. Although several methods of weighting propor-
tions exist, we used the Freeman-Tukey method as we have
evaluated its performance previously in meta-analysis [23,64]. The
choice of weighting proportions approach does not change the
results of a meta-analysis importantly. We assessed heterogeneity
visually and explained heterogeneity using a priori explanations of
heterogeneity, specifically, geographic location of the study.
Common methods of assessing heterogeneity do not perform well
with proportions and appear to overestimate heterogeneity even
when it is low [27].
Although in 2011, the use widespread use of HT seems
misguided, HT has been broadly applied in clinical medicine for
several decades. There is, however, consensus that HT is effective
at climacteric symptoms reduction and osteoporosis prevention
[65,66]. Although many women benefit from intermittent HT use,
the concerns about longer-term adverse events frequently
outweigh the short term benefits. In 2005, the boards of the
international, the Asian pacific, the European and the North
American menopause society conducted post-hoc analyses of the
WHI trial and noted that advanced age of the participants was
importantly associated with adverse events. Concern about
adverse events has also diminished the use of HT. HT use has
declined by up to 62% since the WHI [67,68]. In addition to
decreased HT use, several locations have witnessed a potentially
associated decrease in breast cancers.
It is important to recognize that it is difficult for patients to make
informed decisions as many people obtain their health information
from the media, particularly the internet. The issue is that websites
can be of variable quality and may promote anti-evidence-based
information [69] or may diminish the risks of HT while
highlighting the benefits, or vice versa. As healthcare providers,
physicians should either initiate or engage in discussions raised by
the patients about HT, and recognize that this is an important
opportunity to guide patients to evidence-informed sources of
information, such as National women’s health Resource Center, a
non-profit resource aimed at providing up-to-date information for
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informing women that climacteric symptoms may be short-lasting
and benign, and should be aware of the balanced effectiveness and
risks of HT based on their individual situations [4].
In conclusion, HT has important adverse events, especially
towards breast, many menopausal women are uncertain about the
benefits and risks of HT indeed. Sources of reliable information
may be an important challenge for patients. As health care
providers, it is important to discuss both the benefits and risks with
women and make the decision based on their culture, personal
experience and readiness, especially in the developing countries.
Providing a standard protocol for administration of HT, routine
follow-up health examinations and instituting health teaching
prior to prescription may be reasonable steps to assure HT is
appropriately used and women remain informed and protected.
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